A Study Evaluating the Safety, Activity, and Pharmacokinetics of GDC-6036 in Combination with Other Anti-Cancer Therapies in Participants with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutation [64]. This evidence concerns the gene KRAS and cancer.